Perrigo's Q2 Update: Share Gains Help, but 2.4% Volume Drop Keeps the Turnaround on Trial

Q2 reset the test of Perrigo's turnaround

This quarter did not settle the story on Perrigo's turnaround; it reset the scoreboard. Management is showing better execution inside the business, but revenue still slipped. The key question now is whether market share gains and improving internal trends can turn into real growth, or whether investors will keep treating this as a work in progress.

What improved

Perrigo said it continued to execute its Three-S plan, with market share growth in U.S. store-brand OTC and key European brands. It also reaffirmed its full-year 2026 outlook and said it expects sequentially stronger second-half performance. On the portfolio side, the company completed the Dermacosmetics divestiture and continues strategic reviews of Infant Formula and Oral Care.

Those are useful signs that the part of the business under management's control is improving. The issue is that better operations have not yet translated into clean top-line growth.

What still held results back

Volume/mix fell 2.4% and pricing fell 0.7%. That is why this remains a "show me" quarter. Share gains suggest Perrigo's products are staying relevant, but they do not fully offset a soft category backdrop when price and volume both move the wrong way.

The leadership change also adds a fresh execution lens. The June 8 leadership transition, with Albert Manzone named interim president and CEO, means investors now have a cleaner test of whether the turnaround is systemic rather than tied to one leader.

Share gains matter, but they are not enough by themselves

The core dynamic is straightforward: market share gains show Perrigo is winning some buyer and consumer conversations, but they do not by themselves mean the revenue engine is running better.

Why the share gains matter

Share gains usually mean the company's products, pricing architecture, and commercial execution are holding up well even in a soft environment. Perrigo's reported share gains support that read. In a turnaround story, that is often the first positive sign before headline growth fully turns.

Why the revenue picture still looks weak

The missing piece is conversion into sales and earnings. In this quarter, pricing declined 0.7% and volume/mix decreased 2.4%, so stronger share did not prevent a softer revenue outcome. That is the bear case: share gains are encouraging, but they do not create more revenue if price cannot hold and demand stays weak.

That is also why the next few quarters matter so much. Management is looking for channels to normalize and for the business to benefit from a healthier demand pattern. If that happens, share gains can start to show up more clearly in volume and sales. If not, the story remains a promising operating improvement without real growth yet.

What investors need to see next

This quarter improved the setup, but it did not prove the payoff. The next check should focus on three things:

• whether market share gains continue as the category backdrop improves
• whether volume/mix stops falling and begins to recover
• whether pricing stabilizes as the company moves into a stronger second half

Until that conversion happens, Perrigo's best description is still improving fundamentals, unproven growth.